Trial Profile
An Open Label Phase 2 Trial of Venetoclax With Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 14 Dec 2021 Results assessing the Ibr+ven combination for a fixed duration of 2 years after initial ibrutinib well-tolerated, effective, oral, targeted therapy regimen for patients with relapsed/refractory CLL, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 01 Sep 2021 Status changed from active, no longer recruiting to completed.
- 19 Jul 2019 Status changed from recruiting to active, no longer recruiting.